

## CORRECTION OPEN



# Correction: Halting ErbB-2 isoforms retrograde transport to the nucleus as a new theragnostic approach for triple-negative breast cancer


Santiago Madera , Franco Izzo, María F. Chervo, Agustina Dupont, Violeta A. Chiauzzi, Sofia Bruni, Ezequiel Petrillo, Sharon S. Merin, Mara De Martino, Diego Montero, Claudio Levit, Gabriel Lebersztein, Fabiana Anfuso, Agustina Roldán Deamicis, María F. Mercogliano, Cecilia J. Proietti , Roxana Schillaci , Patricia V. Elizalde and Rosalía I. Cordo Russo

© The Author(s) 2023

*Cell Death and Disease* (2023)14:833; <https://doi.org/10.1038/s41419-023-06339-1>

Correction to: *Cell Death and Disease* <https://doi.org/10.1038/s41419-022-04855-0>, published online 09 May 2022

The original version of the manuscript contained an error in Fig. 1H and its corresponding Source data (Fig. S9C). Specifically, the  $\beta$  tubulin and Histone H3 blots corresponding to MDA-231 cells in the bottom panel of Fig. 1H were unintentionally mistaken while assembling the figures. We have rectified this issue by including the correct blots for  $\beta$  tubulin and Histone H3 controls in MDA-231 cells within the corrected Fig. 1H. Additionally, the corrected Source data is available in the corrected Fig. S9C. This error in the loading control blots does not impact in the interpretation of the results presented in Fig. 1H, nor does it affect the general conclusions of Fig. 1 or of the entire article. The authors sincerely apologize for any confusion the error may have caused. The corrected figures can be found below. The original article has been corrected.



**Fig. 1 R2 evicts WTERbB-2 and ErbB-2c from the nucleus of BC cells.** **A** Left: Representative WB of ErbB-2 expression. Right: signal intensities of ErbB-2c and WTERbB-2 were analyzed by densitometry from three independent WBs performed as indicated. Fold change was calculated by normalizing the absolute levels of each ErbB-2 isoform to those of  $\beta$  tubulin, setting the value of vehicle-treated cells to 1. **B** Representative WB of cell lysates with the indicated phosphospecific or total antibodies. **C, D** ErbB-2 immunofluorescence (IF) in cells treated with R2 or vehicle (24 h). Bottom panels: quantitative analysis of ErbB-2 subcellular localization. Fluorescence intensity of nuclear, cytosolic, and membrane ErbB-2 was quantified and is plotted as percentage (mean  $\pm$  SD,  $n = 50$  per group) relative to total ErbB-2 in each cell. **E** Inhibition of NERbB-2 localization in cells from **C, D** (mean  $\pm$  SEM). For **C, D** vs **A**:  $P < 0.001$ ; for **C, A** vs **B**:  $P < 0.01$ , for **D** vs **B**:  $P < 0.05$ . **F** Nuclear and cytosolic lysates were analyzed by WB. Fold change was calculated for each compartment by normalizing ErbB-2 levels in treated vs control cells (value set to 1). **G** ErbB-2 and Stat3 were localized by IF and confocal microscopy in cells treated as in (**D**). Merged images show colocalization in yellow. The insets show boxed areas in detail. Right: Quantitative analysis of colocalization with Manders' coefficients (M1 and M2, mean  $\pm$  SEM,  $n = 50$  per group). **H** Subcellular distributions of AR and c-Jun evaluated as in (**F**). **I, J** Cells were pretreated with R2 (100  $\mu$ M) or vehicle for 24 h and then treated with HRG $\beta$ 1 (60 min) (**I**) or MPA (90 min) (**J**). ErbB-2 localization and NERbB-2 levels are depicted as in (**C**). ns: not significant, \*\*\* $P < 0.001$ . For (**A–J**),  $n = 3$ . Original uncropped WB images are shown in Fig. S9.

The original article has been corrected.

## ADDITIONAL INFORMATION

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s41419-023-06339-1>.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023